Brand Name | Status | Last Update |
---|---|---|
animi-3 | unapproved drug other | 2013-02-06 |
animi-3 with vitamin d | unapproved drug other | 2011-05-23 |
bal-care dha | unapproved drug other | 2012-05-01 |
bal-care dha essential | unapproved drug other | 2012-05-01 |
bp vit 3 | unapproved drug other | 2025-02-13 |
c-nate dha | unapproved drug other | 2024-01-22 |
citranatal 90 dha | unapproved drug other | 2024-01-08 |
citranatal assure | unapproved drug other | 2024-01-08 |
citranatal bloom dha | unapproved drug other | 2020-04-06 |
citranatal dha | unapproved drug other | 2020-07-28 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Osteoporosis | D010024 | EFO_0003882 | M81.0 | 1 | — | — | 1 | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Lung neoplasms | D008175 | — | C34.90 | — | 2 | 1 | — | — | 3 |
Non-small-cell lung carcinoma | D002289 | — | — | 1 | 1 | 1 | — | — | 3 |
Lymphoma | D008223 | — | C85.9 | — | 1 | 1 | — | — | 2 |
Depression | D003863 | — | F33.9 | — | — | 1 | — | — | 1 |
Major depressive disorder | D003865 | EFO_0003761 | F22 | — | — | 1 | — | — | 1 |
Depressive disorder | D003866 | EFO_1002014 | F32.A | — | — | 1 | — | — | 1 |
Hodgkin disease | D006689 | — | C81 | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Carcinoma | D002277 | — | C80.0 | 2 | 1 | — | — | — | 2 |
Colorectal neoplasms | D015179 | — | — | 1 | 1 | — | — | — | 2 |
Neoplasms | D009369 | — | C80 | 1 | 1 | — | — | — | 2 |
Non-hodgkin lymphoma | D008228 | — | C85.9 | — | 1 | — | — | — | 1 |
Multiple myeloma | D009101 | — | C90.0 | — | 1 | — | — | — | 1 |
Squamous cell carcinoma of head and neck | D000077195 | — | — | 1 | 1 | — | — | — | 1 |
Squamous cell carcinoma | D002294 | — | — | 1 | 1 | — | — | — | 1 |
Esophageal neoplasms | D004938 | — | C15 | — | 1 | — | — | — | 1 |
Adenocarcinoma | D000230 | — | — | — | 1 | — | — | — | 1 |
Obesity | D009765 | EFO_0001073 | E66.9 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Melanoma | D008545 | — | — | 2 | — | — | — | — | 2 |
Prostatic neoplasms | D011471 | — | C61 | 1 | — | — | — | — | 1 |
Renal cell carcinoma | D002292 | EFO_0000376 | — | 1 | — | — | — | — | 1 |
Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | — | — | — | — | 1 |
Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 1 | — | — | — | — | 1 |
Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | — | — | — | — | 1 |
Head and neck neoplasms | D006258 | — | — | 1 | — | — | — | — | 1 |
Postmenopausal osteoporosis | D015663 | EFO_0003854 | — | 1 | — | — | — | — | 1 |
Drug common name | Doconexent |
INN | doconexent |
Description | All-cis-docosa-4,7,10,13,16,19-hexaenoic acid is a docosahexaenoic acid having six cis-double bonds at positions 4, 7, 10, 13, 16 and 19. It has a role as a nutraceutical, an antineoplastic agent, a human metabolite, a Daphnia tenebrosa metabolite, a mouse metabolite and an algal metabolite. It is a docosahexaenoic acid and an omega-3 fatty acid. It is a conjugate acid of a (4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoate. |
Classification | Small molecule |
Drug class | — |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O |
PDB | — |
CAS-ID | 6217-54-5 |
RxCUI | — |
ChEMBL ID | CHEMBL367149 |
ChEBI ID | 28125 |
PubChem CID | 445580 |
DrugBank | DB03756 |
UNII ID | ZAD9OKH9JC (ChemIDplus, GSRS) |